Moberg Derma reveals plan to list on NASDAQ OMX
This article was originally published in Scrip
Executive Summary
Moberg Derma has dusted off its plans to float on the NASDAQ OMX in Stockholm, albeit with a lower price and fund raising target. The Swedish dermatology-focused pharma company has applied to raise SEK 74 million ($12.3 million) by issuing 2,551,724 shares at SEK 29 each. Last December, the company pulled its planned offering of 3.1 to 3.8 million shares at SEK 37 to SEK 45 each, citing insufficient demand to ensure a successful offering.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.